• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Surrozen Inc. (Amendment)

    2/14/23 4:00:45 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email
    SC 13G/A 1 tm234999d20_sc13ga.htm SC 13G/A

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Surrozen, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    86889P109

     

     

    (CUSIP Number)

     

    December 31, 2022

     

     

     

     

    (Date of Event which Requires Filing of this Statement)

     

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 86889P109

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors LP

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    833,333 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    833,333 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,333 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.3% (1)(2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    IA, PN

     

     

    (1)Includes 833,333 shares of common stock (“Common Stock”) of Surrozen, Inc. (the “Issuer”) issuable upon exercise of the 2026 Warrants (as defined in Item 4) directly held by 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Funds”).
    (2)

    Based on 35,122,863 shares of the Common Stock of the Issuer outstanding as of November 10, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 14, 2022, together with the shares that would be issued in connection with the exercise of the 2026 Warrants.

     

     

     

     

    CUSIP No. 86889P109

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors (GP) LLC

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    833,333 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    833,333 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,333 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.3% (1)(2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    HC, OO

     

     

    (1)

    Includes 833,333 shares of Common Stock of the Issuer issuable upon exercise of the 2026 Warrants directly held by the Funds.

    (2)Based on 35,122,863 shares of the Common Stock of the Issuer outstanding as of November 10, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on November 14, 2022, together with the shares that would be issued in connection with the exercise of the 2026 Warrants.

     

     

     

     

    CUSIP No. 86889P109

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Felix J. Baker

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    833,333 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    833,333 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,333 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.3% (1)(2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    IN, HC

     

     

    (1)Includes 833,333 shares of Common Stock of the Issuer issuable upon exercise of the 2026 Warrants directly held by the Funds.
    (2)Based on 35,122,863 shares of the Common Stock of the Issuer outstanding as of November 10, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on November 14, 2022, together with the shares that would be issued in connection with the exercise of the 2026 Warrants.

     

     

     

     

    CUSIP No. 86889P109

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Julian C. Baker

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    833,333 (1)

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    833,333 (1)

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    833,333 (1)

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.3% (1)(2)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    IN, HC

     

     

    (1)Includes 833,333 shares of Common Stock of the Issuer issuable upon exercise of the 2026 Warrants directly held by the Funds.
    (2)Based on 35,122,863 shares of the Common Stock of the Issuer outstanding as of November 10, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on November 14, 2022, together with the shares that would be issued in connection with the exercise of the 2026 Warrants.

     

     

     

     

    Amendment No. 1 to Schedule 13G

     

    This Amendment No. 1 to Schedule 13G amends and restates the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a)Name of Issuer:

     

    Surrozen, Inc. (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    171 Oyster Point Blvd, Suite 400

     

    South San Francisco, CA 94080

     

    Item 2(a)Name of Person Filing:

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons.

     

    Item 2(b)Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c)Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (“Common Stock”).

     

    Item 2 (e)CUSIP Number:

     

    86889P109

     

     

     

     

    Item 3If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

     

    (j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as shares of Common Stock that may be acquired upon exercise of warrants exercisable at any time on a 1-for-1 basis for $11.50 per share into Common Stock expiring August 11, 2026 (the “2026 Warrants”).

     

    The information set forth below is based on 35,122,863 shares of Common Stock outstanding as of November 10, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

     

     

     

    Holder  Number of Shares of Common
    Stock we own or have the right
    to acquire within 60 days
       Percent of Class
    Outstanding
     
    667, L.P.   61,592    0.2%
    Baker Brothers Life Sciences, L.P.   771,741    2.1%
    Total   833,333    2.3%

     

    The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    The Adviser GP is the sole general partner of the Adviser. Pursuant to the management agreements, as amended, among the Adviser, Life Sciences and 667 and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9Notice of Dissolution of Group:

     

    N/A

     

    Item 10Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2023

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

     

         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      /s/ Julian C. Baker
      Julian C. Baker
     
      /s/ Felix J. Baker
      Felix J. Baker

     

     

     

    Get the next $SRZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Surrozen with a new price target

    H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

    1/30/25 7:17:42 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen upgraded by Guggenheim with a new price target

    Guggenheim upgraded Surrozen from Neutral to Buy and set a new price target of $45.00

    1/3/25 7:50:23 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B of A Securities initiated coverage on Surrozen with a new price target

    B of A Securities initiated coverage of Surrozen with a rating of Buy and set a new price target of $11.00

    10/11/21 7:02:26 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Tcg Crossover Gp Ii, Llc claimed ownership of 1,274,010 shares (SEC Form 3)

    3 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/28/26 5:51:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Operating Officer Williams Charles O

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/26/26 4:39:41 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Column Group Iii Gp, Lp bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:35:33 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kutzkey Tim bought $641,597 worth of shares (32,507 units at $19.74) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    1/20/26 7:31:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr

    2/5/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen to Present at Upcoming Healthcare Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern Time 8th Annual Evercore Healthcare Conference on December 3, 2025Surrozen Fireside Chat at 12:25 PM Pacific Time/3:25 PM Eastern Time Interested parties may access the audio webcast for the confer

    11/25/25 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement material to acceptance of employment with Surrozen. The awards were granted under Surrozen's 2025 Equity Inducement Plan and provides for the granting of equity awards to new employees of Surrozen in

    11/12/25 5:01:40 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

    SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    2/5/26 4:28:31 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Inc. filed SEC Form 8-K: Leadership Update

    8-K - Surrozen, Inc./DE (0001824893) (Filer)

    1/30/26 4:08:58 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.

    SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)

    1/22/26 6:55:10 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    View All

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

    SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

    4/5/23 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

    9/23/21 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Financials

    Live finance-specific insights

    View All

    Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

    Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

    3/22/23 4:01:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

    SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

    3/20/23 4:30:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/14/24 4:34:39 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/13/24 5:42:02 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/8/24 11:26:54 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care